Gilead HIV drug elvitegravir does well in Phase III test

Gilead Sciences Inc. said Wednesday that an antiretroviral drug it’s testing against HIV-1 infection did well in a Phase III clinical trial.
The drug, elvitegravir, met the primary endpoint, or goal, of the study, which was “non inferiority” to another drug, raltegravir.